(Updated - May 25, 2023 2:14 PM EDT)

Oppenheimer analyst Jay Olson upgraded Mirati Therapeutics (NASDAQ: MRTX) from Perform ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE